Cover Image

Sensitivity detection of Abacavir in human through SNP detection of HLA-B*5701 allele

Tanushree Mitra*, Shivshankar Kumdale, Sameer Chowdhary, Amol D. Raut


The main objective of this study was to make sure whether randomly taken 12 samples were sensitive to abacavir. The genomic DNA from 12 blood sample were extracted by phenol chloroform DNA extraction method, extracted genomic DNA were amplified and sequenced, thereafter SNPs were detected. Every sample had shown the presence of normal base at SNP position. This study indicated, those randomly taken 12 patients were sensitive to abacavir, so they can consume abacavir if they get infected with HIV.


Abacavir; Sensitivity; HIV; Genomic DNA; HLA-B*5701.

Full Text:



Mallal S, Phillips E, Carosi G et al. for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.

Pérez Prior N, RocherMilla A, Soler Company E, Flores Cid J, SarriaChust B.

Farm Hosp. 2009 May-Jun;33(3):155-60. Spanish.

Sayer DC, Cassell HS, Christiansen FT: HLA-B * 27 typing by sequence-specific amplification without DNA extraction. MolPathol 1999; 52: 300-301.

Telenti A, Aubert V, Spertini F: Individualizing HIV treatment- pharmacogenetics and immunogenetics. Lancet 2002; 359: 722-723.

Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir re challenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 30: 1419-1420.

Hetherington S, McGuirk S, Powel G et al., Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. ClinTher 2001; 23: 1603-1614.

Cutrell AG, Hernandez JE, Fleming JW et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38: 2171-2172.

Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence based typing. Tissue Antigens 2005; 65: 571-574.

Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59: 591-593.

Peyriere H, Guillemin V, Lotthe A, et al., Reasons for early abacavir discontinuation in HIV- infected patients. Ann Pharmacother 2003; 37: 1392-1397.

Saag M, Balu R, Phillips E et al. for the Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen B* 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46: 1111-1118.

Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening of human leukocyte anytigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquire Immune Defic Syndrome 2007; 45: 1-3.

Gerber BO, Pichler WJ: Cellular mechanisms of T-cell mediated drug hypersensitivity. Curr Opin Immunol 2004; 16: 732-737.



  • There are currently no refbacks.

Copyright (c) 2016 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.